Every cell has evolved sophisticated machinery to regulate the expression and function of proteins by degradation. This elaborate mechanism involves the controlled ubiquitination of protein substrates by E3 ligase complexes.
Using rationally designed small molecule degraders (also known as molecular glues) our goal is to hijack this natural process and redirect the degradation machinery to specific disease-causing proteins.
28.10.2024
Monte-Rosa Therapeutics enters billion-dollar partnership with Novartis (startupticker.ch)
25.06.2021
Monte Rosa Therapeutics raises USD222 million in successful IPO (startupticker.ch)
19.03.2021
Monte Rosa closes $95 million series C round (startupticker.ch)
11.03.2021
New appointments at life sciences startups (startupticker.ch)
28.10.2020
Seasoned executives for startups (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
Website:
www.monterosatx.com/
Headquarter:
Basel
Foundation Date:
April 2018
Technology: